ESR2 and neoplasm: Moreover, the target selection of ERβ agonists must be evaluated carefully to prevent the stimulation of several ERβ isomers (ERβ2, ERβ3, ERβ4, and ERβ5) from activating tumour proliferation in PCa cases.